What can our blood tell
Each of us at least once in his life donated blood for analysis and received a piece of paper on his hands with letters, numbers and units of measure. Then…

Continue reading →

Alternative medicine: how fools are made of us
In the era of the development of the Internet, you can “google” any disease: you enter the symptoms, and the search engine gives you a list of medical sites, videos,…

Continue reading →

Fibromyalgia, or where does this pain come from? ..
The main symptom of fibromyalgia is spilled muscle pain that lasts more than three months. Experts put forward several theories about the possible causes of its occurrence. Guzel Tabeeva, professor…

Continue reading →

How much does prostate cancer cost?

The costs of treating cancer usually exceed insurance coverage … So: the economic burden of prostate cancer alone in Russia amounted to 3.7 billion rubles a year. These and other important data were the result of a study conducted by the Research Institute of Clinical and Economic Expertise and Pharmaceutical Economics of the Russian National Research Medical University named after Pirogov.

Prostate cancer (PCa) is one of the most commonly diagnosed oncological diseases in the male population of Russia. Over the past ten years, there has been an increase in the incidence and mortality rates from this disease. So, prostate cancer ranks third (11% of the total) in the structure of the primary incidence of malignant neoplasms. In the period from 2000 to 2010. a high rate of increase in the incidence of prostate cancer was noted – an average of 9.83% per year. According to 2010 data, there is a continuation of the growth trend in mortality rates from prostate cancer – compared with 2009, mortality from prostate cancer increased by 2.1%.

See also: Liver cancer, or Why the diagnosis is random.

Reference: Prostate cancer is a malignant neoplasm that occurs in men, mainly middle-aged and elderly. An important role in the development of the disease is played by androgens – male sex hormones that can contribute to tumor growth.

Reference: Prostate cancer is a malignant neoplasm that occurs in men, mainly middle-aged and elderly. An important role in the development of the disease is played by androgens – male sex hormones that can contribute to tumor growth.

The main risk factors for prostate cancer are age, family history, and ethnicity. Also, risk factors may include nutritional characteristics, but these data today do not have accurate confirmation.

A study of the socio-economic burden of prostate cancer suggests that the total cost of treating all patients with this disease is 3,674,032,748 rubles. The average cost per patient per year is at 33,270 rubles. At the same time, the main volume of expenses falls on patients with an initially established diagnosis, and the costs of treating patients in the late stages of the disease are 6 times lower. This suggests that in order to increase the effectiveness of therapy and reduce the level of mortality from prostate cancer, it is necessary to treat patients at all stages of the disease, which will increase their life expectancy in general.

Despite the fact that the disease occurs mainly in elderly men, late diagnosis, high morbidity and mortality lead to a decrease in the contribution of the economically active population to GDP, since, according to statistics, on average in Russia 34.4% of people continue to work after reaching retirement age.

When considering prostate cancer from the point of view of the economic burden for the state, it is also worth noting that until recently there were no standard approaches to treating patients with a progressive form of this disease, which could significantly increase survival and improve the quality of life of patients.

Recent studies of the biology of metastatic hormone-resistant prostate cancer have led to the development of innovative effective drugs that cope with this task. Such drugs were registered in Russia in 2011 – 2012 and are already used in patients with disease progression during or after chemotherapy. From the point of view of pharmacoeconomic analysis, the costs of such treatment are comparable to the state expenses for other targeted oncological drugs. The use of new drugs for the treatment of prostate cancer in widespread clinical practice will reduce mortality rates, as happened in the recent past with hematologic diseases, lung and breast cancer.

“Pharmacoeconomic analysis showed that the cost of a patient’s saved year of life when using new drugs registered in Russia today is comparable to the same costs of drugs already included in the list of vital drugs. This suggests the acceptability of using such therapy for the healthcare system of the Russian Federation,” – commented Elena Derkach, senior researcher at the Laboratory for Clinical and Economic Analysis, Research Institute of Clinical and Economic Expertise and Pharmacoeconomics, Russian State Medical University.

Pros and cons of alternative medicine
Alternative medicine can help with a mass of various diseases, but before you make a choice in its direction, you need to familiarize yourself with all its advantages and disadvantages.…

...

Blood for analysis. We rent out correctly!
We donate blood for analysis correctly. 9022.jpeg Just think, what is the importance - to donate blood correctly! But still, there are some subtleties in this matter. Before donating blood…

...

Why "grapes" grew in the nose
Doctors, speaking of polypous rhinosinusitis (the disease is so correctly called), always mention a bunch of grapes. Like, polyps in the nose are very similar to her in shape. However,…

...

Pros and cons of alternative medicine
Alternative medicine can help with a mass of various diseases, but before you make a choice in its direction, you need to familiarize yourself with all its advantages and disadvantages.…

...